Amgen Inc.
439.26USD
-8.0200 (-1.79%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on AMGN.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10,054 | 8,618 | 9,866 | 9,557 | 9,179 | 8,149 | 9,086 | 8,503 |
| Cost of Revenue | 2,811 | 2,744 | 2,976 | 3,082 | 3,011 | 2,968 | 3,112 | 3,310 |
| Gross Profit | 7,243 | 5,874 | 6,890 | 6,475 | 6,168 | 5,181 | 5,974 | 5,193 |
| Operating Income | 3,514 | 2,666 | 2,720 | 2,526 | 2,656 | 1,178 | 2,311 | 2,047 |
| Net Income | 2,375 | 1,819 | 1,333 | 3,216 | 1,432 | 1,730 | 627 | 2,830 |
| EPS (Diluted) | $4.37 | $3.34 | $2.46 | $5.93 | $2.65 | $3.20 | $1.16 | $5.22 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)